

ANCO FAX News

Association of Northern California Oncologists
Post Office Box 151109, San Rafael, California 94915-1109
Voice: (415) 472-3960 • FAX: (415) 472-3961
execdir@anco-online.org • www.anco-online.org

Vol. 18, No. 5

March 8th, 2019

The *ANCO FAX News* focuses on ANCO's core activities—advocacy, clinical and professional education, and *Association and membership news*. While membership mailings and e-mail/FAX broadcasts continue, the *ANCO FAX News* summarizes this information in a regular forum of important news to members. Contact the ANCO office for additional information regarding any item published in the *ANCO FAX News*. Find the *ANCO FAX News* online at www.anco-online.org/pubs.html.

In this issue:

- AMA RVS RUC survey
- MIPS adjustment corrections
- Security prescription form update
- *Multidisciplinary Management of Cancers*
- *2019 Hematologic Malignancies Updates*

The *ANCO FAX News* is FAXed to Individual Member practices, and e-mailed to Group, Institutional, and Corporate (contacts)

Members. The next regular *ANCO FAX News* will be published on March 22nd. Send your comments or contributions to ANCO, P.O. Box 151109, San Rafael, CA 94915-1109; Voice: (415) 472-3960; FAX: (415) 472-3961; execdir@anco-online.org.

The *ANCO FAX News* has information for every member of your practice or organization. Pass it along!

- ☐ Physician Members
- ☐ Nurses & Office Managers
- ☐ Office Staff
- ☐ Colleagues & Representatives

The *Association of Northern California Oncologists* (ANCO) is an association of hematologists/oncologists dedicated to promoting high professional standards of cancer care by providing a forum for the exchange of ideas, data, and knowledge.

The material contained in the *ANCO FAX News* is intended as general information for ANCO members. Because diagnostic, treatment, contracting, coding, and billing decisions should be made on a case-by-case basis, any such information contained in the *ANCO FAX News* may not apply in any given situation. Members are encouraged to contact their own consultants or advisors to obtain specific advice on matters relating to contracting, coding, and billing. The information contained in the *ANCO FAX News* should not be used as a substitute for such advice.

ADVOCACY

[Editor's Note: ANCO is a member of the Association of Community Cancer Centers (ACCC) and a state/regional affiliate of the American Society of Clinical Oncology (ASCO). ANCO and the Medical Oncology Association of Southern California (MOASC) are members of the California Medical Association's (CMA) Council on Legislation, House of Delegates, and specialty delegation. ANCO meets regularly with these and other organizations to discuss issues of importance to hematology/oncology practices and people living with cancer. We continually seek input from members on agenda items for these meetings. Send your issues to the ANCO office.]

ACCC, ASCO, ASH, COA, and National Legislative & Regulatory Issues

ASCO members who are practicing oncologists may have received an email inviting them to participate in the *American Medical Association's (AMA) Specialty Society Relative Value Scale (RVS) Update Committee (RUC) survey for physician office visits (99202-99205, 99211-99215) and new prolonged services code (99xxx)*. This important survey will help ASCO, in concert with the RUC, recommend accurate relative values for physician work and direct practice expenses to CMS. ASCO members are encouraged to participate if they are invited to take the survey.

ANCO and ASCO ask members to contact their *Congressional Representatives* and urge them to support HR913, the *Clinical Treatment Act*, that would ensure states cover routine care costs of participation in an approved clinical trial for Medicaid enrollees with life-threatening conditions. Routine costs are defined to include non-experimental costs of treating a patient who is participating in a clinical trial such as physician visits or laboratory tests—standard care that would be provided regardless of whether a patient participates in a clinical trial. In order to provide depth as to why this legislation is so important, ASCO is looking for information and stories that you or your practice may have related to the denial of clinical trial coverage for patients under Medicaid. Please e-mail Kate Flannigan at katherine.flannigan@asco.org with any information, questions, or comments related to the topic.

ASCO has been informed that some oncology practices and providers in MIPS have received inaccurate payment adjustments as a result of Medicare Part B drug costs incorrectly being included in the adjustments. CMS recently published a fact sheet outlining the 2019 MIPS Payment Adjustments based on 2017 MIPS Scores explaining program definitions, scoring and other important aspects of the payments made to physicians. Read the fact sheet at ascopubs.org/doi/abs/10.1200/JCO.18.01616. If CMS overpaid a claim based on this calculation error, then you will get a notification for recoupment from your MAC. If CMS underpaid a claim, it will be adjusted. If you believe your adjustment is incorrect for any reason, please contact CMS' QPP help desk at (866) 288-8292; additional questions may be e-mailed to macra@asco.org.

CMS opened the data submission period for MIPS eligible clinicians who participated in Year 2 (2018) of the QPP. Data can be submitted and updated any time up to April 2nd, with two exceptions—CMS Web Interface users need to report their quality performance category data by March 22nd; clinicians who reported quality measures via Medicare Part B claims throughout the 2018 performance year will have their quality data sent to CMS by their MAC. Submit your 2018 MIPS data by visiting the QPP website at qpp.cms.gov/login?. In addition, **the QOPI Reporting Registry, a QCDR brought to you by ASCO and ASTRO, is your one-stop shop for 2019 MIPS reporting.** Visit practice.asco.org/quality-improvement/quality-programs/qopi-reporting-registry? for more information.

ASCO has published new standards on the safe handling of hazardous drugs in the *Journal of Clinical Oncology* at ascopubs.org/doi/abs/10.1200/JCO.18.01616. ASCO's standards largely endorse best practices issued by other stakeholder groups for safely handling hazardous drugs but offer alternatives in several key areas where more research is needed to identify

evidence-based safety measures. ASCO's safe handling standards differ from existing standards in four areas: 1) the use of medical surveillance, 2) closed system transfer devices (CSTDs), 3) external ventilation of containment secondary engineering controls (C-SEC) or containment segregated compounding areas (C-SCA), and 4) alternative duties. In a systematic review of the available scientific literature, ASCO found that recommended practices in these areas are currently not supported by high-quality, unbiased studies on health outcomes. Read the standards at www.asco.org/advocacy-policy/asco-in-action/new-standards-safe-handling-hazardous-drugs-focus-developing-evidence; download the slides from ASCO's webinar on the standards at www.asco.org/sites/new-www.asco.org/files/content-files/practice-and-guidelines/documents/Handling_Hazardous_Drugs_Webinar_Feb152019.pdf.

CMA, MOASC, and State Legislative & Regulatory Issues

The *California Oncology Political Action Committee* (or CalCancerPAC), formed by ANCO and MOASC, supports candidates sensitive to the needs of hematologists/oncologists and people living with cancer in California. ANCO membership dues include a contribution to the CalCancerPAC.

With the support of the *National Oncology State Network* (NOSN), ANCO and MOASC are working to create the *California Cancer Caucus*. The goal of the *California Cancer Caucus* is to bring the Capitol community and the oncology community together to improve the access, care, treatment, research, and support for those fighting cancer. The *Caucus* seeks to improve communication and education between cancer care stakeholders and health policy decision makers to improve public policy that has a direct impact on the continuum of care for people living with cancer.

Implementation of the new state law (AB1753) that requires security prescription forms to have a uniquely serialized number will be postponed thanks to a legislative fix (AB149) heading to the Governor's desk for signature. AB149 postpones implementation of AB1753 to a date that will be determined by the *Department of Justice* that is no later than January 1st, 2020. In addition, AB149 will also establish a transition period, making any prescription written on a prescription form that was otherwise valid prior to January 1st, 2019, a valid prescription that may be filled, compounded, or dispensed until January 1st, 2021.

thesecondopinion has been serving the California cancer community for 50 years by providing free, comprehensive second opinions to cancer patients and their families. They will celebrate this anniversary with an information and educational luncheon on Thursday, May 9th that will feature a presentation by Charles Graeber, author of *The Breakthrough: Immunotherapy and the Race to Cure Cancer*. For information, visit www.thesecondopinion.org or call (415) 775-9956.

Noridian/JEMAC, DHCS/MediCal, & Private Payers

Noridian Administrative Services is the Jurisdiction E (JE) *Medicare Administrative Contractor* (MAC). Jurisdiction E includes California. Regularly review postings at the *Noridian/JEMAC* website at med.noridianmedicare.com/web/jeb. Recent updates include:

- MLN Connects Provider eNews *Announcements*—Interoperability and Patient Access to Health Data: New Proposals; Quality Payment Program: Payment Adjustment Resource; Reducing Opioid Misuse Letter; New Medicare Card: New an MBI?; Promoting

Interoperability Programs: Attestation Deadline Extended to March 14;
 Interoperability and Patient Access to Health Data: Comments on New Proposals due May 3
Claims, Pricers & Codes—Laboratory Panel Billing Requirements; Average Sales Price Files: April 2019
Events—Open Payments: Transparency and You Call-March 13; Data Interoperability Across the Continuum: CMS Data Element Library Call-March 19; SNF Value-Based Purchasing Program: Phase One Review and Corrections Call-March 20
Publications—HPTCs Code Set: April 2019 Update MLN Matters Article-New; DMEPOS Fee Schedule: April 2019 Update MLN Matters Article-New; NCCI: Modification of MCS Logic for Modifiers Involving PTP MLN Matters Article-New; Medical Documentation: Exchanging the List of eMDR via esMD MLN Matters Article-Revised; How to Use the Medicare Coverage Database Booklet-Revised; SNF Billing Reference Booklet-Revised; Clinical Laboratory Fee Schedule Fact Sheet-Revised; CLIA Edits: HCPCS Codes Subject to and Excluded MLN Matters Article-New; E/M When Performed with Superficial Radiation Treatment MLN Matters Article-Revised; Diagnosis Coding: Using the ICD-10-CM Web-Based Training Course-Reminder; Procedure Coding: Using the ICD-10-PCS Web-Based Training-Reminder

- HPTCs Code Set-April 2019 Update
- DMEPOS Fee Schedule-April 2019 Update
- Modification of the MCS Claims Processing System Logic for Modifier 59, XE, XS, XP, and XU Involving the NCCI

PTP Column One and Column Two Codes

- Multi-Jurisdictional Contractor Advisory Committee (CAC) Meeting Documents
- Implementation to Exchange the List of Medical Documentation Requests (eMDR) for Registered Providers via the Electronic Submission of Medical Documentation (esMD) System-Revised CR11003
- MolDX: Clonoseq Assay for Assessment of Minimal Residual Disease (MRD) in Patients with Specific Lymphoid Malignancies
- MSI Coming March 2019
- HCPCS Codes Subject to and Excluded from CLIA Edits CR11135
- Evaluation and Management (E/M) When Performed with Superficial Radiation Treatment CR11137
- MolDX: Breast Cancer Index (BCI) Gene Expression Test Final LCD-Effective April 16, 2019
- MolDX: Genetic Testing for Lynch Syndrome Final LCD-Effective April 16, 2019
- Medicare Part B Clinical Laboratory Fee Schedule: Revised Information for Laboratories on Collecting and Reporting Data for the Private Payor Rate-Based Payment System SE19006

Forthcoming *Noridian/JEMAC* meetings/webinars/workshops include:

- PECOS Part 1: Full Overview of PECOS Webinar (March 13)
- Appeals I-The Basics Webinar (March 19)
- Telehealth Services Webinar (March 19)

- Appeals II-Appealing a Decision Webinar (March 20)
- Telehealth Services-After Hours Webinar (March 21)
- Appeals III-Appeal Decisions Webinar (March 21)
- Modifier 59, NCCI and MUEs Webinar (March 26)
- Compliance Program-What Every Provider Needs to Know Webinar (March 26)
- PECOS Part 2: Full Overview of PECOS Webinar (March 27)
- Modifier 59, NCCI and MUEs-After Hours Webinar (March 28)
- Independent Diagnostic Testing Facility (IDTF) Enrollment Webinar (April 10)
- Medicare Part A/B Revalidation Webinar (April 24)
- Submitting Your Enrollment Online-Part 1 Webinar (I&A; May 29)
- Submitting Your Enrollment Online-Part 2 Webinar (PECOS; June 26)

Visit med.noridianmedicare.com/web/jeb/education/training-events for more information and to register.

The California *Department of Health Care Services* (DHCS) recently announced it has signed a contract with DXC Technology who will assume all fiscal intermediary duties for Medi-Cal effective October 1st, 2019. The contract with Conduent, the current fiscal intermediary, will expire September 30th.

Anthem Blue Cross's Provider News (March 2019) is now available online at providernews.anthem.com/california. *UnitedHealthcare's Network Bulletin* (March 2019) is now available online at www.uhcprovider.com.

EDUCATION

[Editor's Note: ANCO organizes clinical and professional education meetings throughout the year and throughout Northern California.]

19th Multidisciplinary Management of Cancers: A Case-based Approach

The 19th *Multidisciplinary Management of Cancers: A Case-based Approach* returns to the Silverado Resort and Spa in Napa on March 15-17th. The meeting is sponsored by the *Association of Northern California Oncologists*, *Stanford Cancer Institute*, *UC Davis Comprehensive Cancer Center*, and the *UCSF Helen Diller Family Comprehensive Cancer Center*. For more information, visit www.multicancers.org.

SAVE THE DATES ANCO's 2019 Hematologic Malignancies Updates

ANCO is organizing a series of *Hematologic Malignancies Updates* in 2019 on May 18th in Palo Alto, September 14th in Sacramento, and November 16th in San Francisco. These updates are supported by *AstraZeneca*, *Celgene*, *Janssen Oncology*, *Pharmacyclics*, and *Takeda Oncology*. Watch for the first meeting announcement in late March.

ASCO Annual Meeting

ASCO's 2019 *Annual Meeting—Caring for Every Patient, Learning from Every Patient*—takes place in Chicago from May 31st-June 4th. Learn more and register at meetings.asco.org/am/register-submit-abstracts. Arrive a day early for added learning by taking advantage of opportunities to network and experience in-depth education on timely topics in oncology. Space is limited—learn more and register now at meetings.asco.org/am/seminar-pre-annual-meeting-seminars.

Additional Education Meetings

March 14-16

The Multidisciplinary Thoracic Cancers Symposium

ASCO, ASTRO, & The Society of Thoracic Surgeons

San Diego

(<http://thoracicsymposium.org>)

March 15th

Upcoming Trends in Renal Cell Cancer

CancerCare Connect Education Workshop

(www.cancercare.org/connect_workshops)

March 18th

Advances in the Treatment of Colorectal Cancer

CancerCare Connect Education Workshop

(www.cancercare.org/connect_workshops)

March 19th

Caregiving to Your Loved One with Cancer

CancerCare Connect Education Workshop

(www.cancercare.org/connect_workshops)

March 20th

Triple Negative Breast Cancer and African American Women

CancerCare Connect Education Workshop

(www.cancercare.org/connect_workshops)

March 20th-22nd

45th Annual Meeting & Cancer Center Business Summit

ACCC

Washington, D.C.

(<https://www.accc-cancer.org/home/attend/accc-45th-annual-meeting-cancer-center-business-summit?>)

March 21st

Update on Chronic Lymphocytic Leukemia (CLL)

from the 2018 ASH Annual Meeting

CancerCare Connect Education Workshop

(www.cancercare.org/connect_workshops)

April 3rd

Taking Your Pills on Schedule: Its Importance in Treating Cancer

CancerCare Connect Education Workshop

(www.cancercare.org/connect_workshops)

April 4-5th

2019 Community Oncology Conference

Community Oncology Alliance

Lake Buena Vista FL

(www.coaconference.com)

April 8th

Joys and Challenges of Pets in Your Home When You Have Cancer

CancerCare Connect Education Workshop

(www.cancercare.org/connect_workshops)

April 8-9th

11th Annual Palliative Care Summit

Coalition for Compassionate Care of California

& Children's Hospice Palliative Care Coalition

San Francisco

(cccssummit.org)

April 10th

Progress in the Treatment of Waldenström's

Macroglobulinemia (WM)

CancerCare Connect Education Workshop

(www.cancercare.org/connect_workshops)

April 15th

Managing Eye and Vision Changes Related to Cancer Treatments

CancerCare Connect Education Workshop

(www.cancercare.org/connect_workshops)

April 23rd

Treatment Update on Mantle Cell Lymphoma

CancerCare Connect Education Workshop

(www.cancercare.org/connect_workshops)

April 24th

Update on Diffuse Large B-Cell Lymphoma

CancerCare Connect Education Workshop

(www.cancercare.org/connect_workshops)

April 25th

Progress in the Treatment of Multiple Myeloma

CancerCare Connect Education Workshop

(www.cancercare.org/connect_workshops)

Please contact the ANCO office for more

information about these meetings.

ASSOCIATION & MEMBERSHIP NEWS, RESOURCES, & BENEFITS

[Editor's Note: All ANCO members are also eligible for several tangible benefits.]

Board of Directors

The ANCO *Board of Directors* teleconferenced on February 27th to discuss and/or act upon the following:

- California legislative and regulatory issues
- ANCO travel awards
- 2019 *Board* teleconference and meeting schedule

Contact the ANCO office for additional information on any of these items.

The ANCO *Board of Directors* meets by teleconference and occasionally in person to discuss issues affecting the *Association*, clinical and professional education, and ways to better serve the membership. *Board* teleconferences/meetings are open to individual physician members. The **next regularly scheduled ANCO Board of Directors meeting is scheduled for April 5-6th**. Please call José Luis González, *ANCO Executive Director*, at (415) 472-3960 if you wish to participate in a future teleconference/meeting.

Individual Member News

A current *Directory of Members* is available **online** at www.anco-online.org/pubs.html as a .pdf document. We urge all ANCO members to download their own edition of *The ANCO Directory of Members*. Please verify your *Directory* entry and contact the ANCO office at execdir@anco-online.org with any corrections, additions, and/or deletions.

Group Member News

ANCO initiated a **Group Membership** in 2008 based on a mutual set of perceived values and benefits and a mutual set of interests. The ANCO

Board believes that the *Association* and *The Permanente Medical Group* (TPMG) will each receive value from Group Membership.

ANCO initiated a **Multi-Site Group Membership** in 2010 to encourage all physicians (medical and radiation oncologists) from multi-site and multidisciplinary practices to join. ANCO thanks *Annadel Medical Group/St Joseph's Heritage Healthcare, Diablo Valley Oncology & Hematology Medical Group, EPIC Care, Marin Cancer Care, Pacific Cancer Care, Palo Alto Medical Foundation, and Stockton Hematology Oncology Medical Group* for their multi-site group memberships.

Institutional Member News

ANCO initiated an **Institutional Membership** in 2002. *Department(s) of Hematology and/or Oncology* of accredited, degree granting teaching universities or research institutions are eligible for institutional membership. ANCO thanks the following Institutional Members for their support:

- *Stanford Cancer Center*
- *University of California, Davis, Cancer Center*
- *University of California, San Francisco*

UC San Francisco will host the **5th World Congress on Controversies in Breast Cancer (CoBrCA): When is Less More?** on September 4-6th. For additional information, please visit cobrca.org. ANCO members may use discount code **cobrca10** to receive a 10% discount on registration.

Corporate Member News

ANCO thanks the following **Corporate Members** for their generous support that enables ANCO to provide services to the hematology/oncology community in northern California, and to provide its members and their patients with substantial benefits in the areas of advocacy, education, and information dissemination:

AbbVie • Adaptive Biotechnologies
Agios Pharmaceuticals
Alexion Pharmaceuticals • AMGEN
AMAG Pharmaceuticals • Array BioPharma
Astellas Oncology • AstraZeneca
Bayer Healthcare Pharmaceuticals
Boehringer Ingelheim Pharmaceuticals
Bristol-Myers Squibb Oncology
Celgene • Clovis Oncology • Coherus Biosciences
Daiichi Sankyo • Eisai • EMD Serono • Exelixis
Foundation Medicine • Genentech BioOncology
Genomic Health • Gilead Sciences
Guardant Health • Helsinn Oncology
Heron Therapeutics • Incyte
Ipsen Biopharmaceuticals • Janssen Oncology
Jazz Pharmaceuticals • Kite Pharmaceuticals
Lexicon Pharmaceuticals • Lilly Oncology • Merck
Novartis Oncology • Pfizer Oncology
Pfizer US Biosimilars • Pharmacyclics
Puma Biotechnology • Sandoz Biopharmaceuticals
Sanofi Genzyme • Seattle Genetics
Stemline Therapeutics • Taiho Oncology
Takeda Oncology • Tempus Labs
TerSera Therapeutics • Tesaro
Teva Oncology • Verastem Oncology

We especially wish to thank and welcome *Adaptive Biotechnologies*, *Heron Therapeutics*, *Ipsen Biopharmaceuticals*, *Stemline Therapeutics*, *Tempus Labs*, and *Verastem Oncology* as new Corporate Members for 2019. Please visit www.anco-online.org/assistance.html for **Corporate Member drug reimbursement and patient assistance program information**. ANCO encourages all member practices to use this resource and enroll all patients at the start of treatment in all available and appropriate patient assistance programs.

Genentech BioOncology informs ANCO that the *United States Food and Drug Administration* has approved a subcutaneous version of Herceptin Hylecta for treating HER2 overexpressing breast cancer.

Taiho Oncology informs ANCO that the *United States Food and Drug Administration* has approved Lonsurf tablets for metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma previously treated with at least two prior lines of

chemotherapy that included fluoropyrimidine, a platinum, either a taxane or irinotecan, and if appropriate, HER2/neu-targeted therapy.

Publications, Resources, Services, & Surveys

ASCO is inviting all oncology practices to participate in the 2019 *Survey of Oncology Practice Operations* which aims to give practices a deeper look at a variety of oncology management topics, including productivity, revenue, staffing levels, salaries, expenses, and more. The *Survey* is open through Friday, March 15th. Respondents who complete the *Survey* will receive entry into drawing for a free year of Practice Administrator or other Affiliated Health Professional ASCO membership; a comprehensive report highlighting how your practice compares to others; salary statistics on 30 oncology staff roles; and, a full data set of deidentified data. Learn more and take the *Survey* at www.asco.org/advocacy-policy/asco-in-action/learn-how-your-practice-compares-take-ascos-2019-survey-practice?.

ASCO seeks applications for research grants for projects that use data from CancerLinQ Discovery, an offering of ASCO's CancerLinQ initiative, as a source. CancerLinQ Discover provides curated sets of de-identified data from cancer patients to academic researchers, government agencies, and others in the oncology community to generate practical knowledge that will improve care. With grants of \$32,500 each, ASCO will provide early and mid-career clinical oncology and health service investigators with real-world evidence that can inform their research. Research topics may include—but are not limited to—adoption of treatment guidelines across the U.S.; development of quality measures with the highest impact for clinical care; measuring the impact of educational programs on clinical practices; supportive evidence for informing ASCO policy priorities; or novel research on other topics. The deadline for submitting a research proposal is April 30th. For

more information, visit www.conquer.org/cancerlinq-discovery-research-support-grant.

ASCO has released or updated the following practice recommendations and clinical practice guidelines—management of the neck in squamous cell carcinoma of the oral cavity and oropharynx (www.asco.org/practice-guidelines/quality-guidelines/guidelines/head-and-neck-cancer#/34961); early detection of colorectal cancer (www.asco.org/practice-guidelines/quality-guidelines/guidelines/gastrointestinal-cancer#/34946); treatment of patients with early colorectal cancer (www.asco.org/practice-guidelines/quality-guidelines/guidelines/gastrointestinal-cancer#/34951). **Join ASCO's Practice Guidelines Implementation Network (PGIN) to keep up-to-date on new and updated guidelines and resources and to get involved and participate in guidelines-related initiatives** at www.asco.org/practice-guidelines/quality-guidelines/practice-guidelines-implementation-network-pgin.

ASCO's Clinical Affairs Department provides services, education, and resources to support oncology practices. It offers hands-on assistance in areas such as practice management, quality care assessment and improvement, and efficiency and business intelligence to meet the needs and demands of the current oncology landscape. Resources on the business of oncology, practice management (staffing, technology), practice transformation, and market analysis are available from the *Department*. For more information, visit www.asco.org/practice-guidelines/practice-support.

ASCO's Practice Consulting Services & Support offers personalized services to help practices achieve operational goals. Their team of nationally recognized consultants in oncology practice management is dedicated to assisting practices succeed in today's constantly evolving practice environment. Services include readiness assessment, practice operational assessment,

practice transformation implementation support, analytical services, triage pathways. For more information, visit practice.asco.org. **ASCO's Practice Engagement Program helps administrators, physicians, and other members of the care team navigate ASCO tools, programs, and resources available to help oncology practices respond to the changes occurring in the cancer care delivery system.** **ASCO's Practice Central is a website that serves as an online information hub to help oncology professionals navigate a complicated and ever-changing practice environment—while providing high-quality patient care.** ASCO *Practice Central* offers oncology practices easy-to-access information, tools, and resources that are designed to foster effective business practices and support high-quality patient care. Bookmark *ASCO Practice Central* at practice.asco.org. **Improve your business operations with ASCO's PracticeNET, a collaborative network in which practices share and receive insights to enhance their business operations and quality of care.** Learn more at practice.asco.org/practice-support/practice-benchmarking/practicenet.

The February 2019 issue of ASCO's *Journal of Oncology Practice* (JOP) is available online and features articles entitled *ASCO Standards for Safe Handling of Hazardous Drugs*; *Oral Anticancer Therapy: Management of Drug Interactions*. Visit ascopubs.org/toc/jop/current for more information.

Data abstraction for ASCO's QOPI Round 1 will close on June 3rd. Round 1 final reports will be available approximately two weeks after the round closes. Learn more at practice.asco.org/quality-improvement/quality-programs/quality-oncology-practice-initiative?.

ASCO offers the QOPI Certification Program to recognize QOPI participants who achieve rigorous standards for cancer care. The *QOPI Certification* designation can be used by certified practices to demonstrate an advanced commitment to quality. *The Doctors Company,*

the nation's largest physician-owned medical malpractice insurer, offers up to a 10% premium discount to physicians whose practices have achieved QOPI certification. Learn more at www.thedoctors.com/qcp.

ASCO's 2019 Self-Evaluation App: Breast and Gynecologic Cancers, formerly known as the ASCO MOC App, features six courses, with 20-questions each, on a variety of topics in Breast and Gynecologic Cancers. Test your knowledge and confidence with these multiple-choice questions, which include patient case information, educational links, and answer rationales. Available via the Android and Apple app; learn more at shop.asco.org/sacjan19_2019-self-evaluation-app-breast-and-gynecologic-cancers/.

Managing the cost of cancer care can be overwhelming and ASCO Answers can help your patients. *ASCO Answers* gives your patients practical guidelines for managing the cost of their cancer care. It covers health insurance benefits, information about the *Affordable Care Act*, tips, resources, & more! Learn more and order *ASCO Answers* at shop.asco.org/mccc15_managing-the-cost-of-cancer-care-pack-of-50-booklets/.

ACCC's 2019 Patient Assistance and Reimbursement Guide is an essential tool for cancer program staff to use in helping patients with issues related to the cost of treatment and in meeting reimbursement challenges. The *Guide* features a list of pharmaceutical and non-pharmaceutical patient assistance programs (PAPs), including directions on how to apply and links to enrollment forms. Visit www.accc-cancer.org/home/learn/publications/patient-assistance-and-reimbursement-guide to access this resource. In addition, ACCC has developed a tool for accessing patient assistance and reimbursement programs for use on a desktop, table, or mobile device. The *Financial Advocacy Network* (FAN) app is available at accc-fan-app.org.

NCCN has published and/or updated their

Chemotherapy Order Templates, Clinical Practice Guidelines in Oncology, Drugs & Biologics Compendium, Evidence Blocks, Guidelines for Patients, Imaging Appropriate Use Criteria, and/or Radiation Therapy Compendium for: antiemesis (V1.2019), B-cell lymphomas (V2.2019), breast cancer (V4.2018), cancer-associated venous thromboembolic disease (V1.2019), central nervous system cancers (V1.2019), chronic lymphocytic leukemia/small lymphocytic lymphoma (V3.2019), cutaneous melanoma (V1.2019), distress management (V2.2019), hepatobiliary cancers (V2.2019), kidney cancer (V3.2019), neuroendocrine and adrenal tumors (V1.2019), non-small cell lung cancer (V3.2019), primary cutaneous lymphomas (V2.2019), thyroid carcinoma (V3.2018), thymomas and thymic carcinomas (V1.2019), uterine neoplasms (V3.2019). Go to www.nccn.org for more information.

The Academy of Oncology Nurse & Patient Navigators (AONN+) is pleased to share that the application period for the certification exam being held at the AONN+ Midyear Conference is now open through April 26th. Learn more at aonnonline.org/certification.

Individual Membership Dues for 2019

Membership renewal notices for 2019 were mailed to all members the last week in November. Second notices of membership renewal for 2018 were mailed to all members in early February. If you have not yet done so, then please return your 2019 membership dues to ANCO now to ensure your inclusion in *The ANCO Directory of Members*. Be sure to provide ANCO with your e-mail address and the name(s) and e-mail address(es) of office and/or nurse manager contact(s). Those not renewing their membership by June 30th will be deleted from the *Directory of Members*, and will no longer be eligible for any ANCO benefits. Contact the ANCO office if you do not receive or misplaced your membership dues renewal notice.